drugsTreatmentPhase 2

IPG1094

IPG1094 is a small-molecule inhibitor from Nanjing Immunophage Biotech Co., Ltd, in registered phase 2 trials for metastatic cancer.

IPG1094 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Nanjing Immunophage Biotech Co., Ltd, in metastatic cancer. Described in the registry record as a an inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

See it in action

Described in the registry record as a an inhibitor; the trial entries below carry the sponsor's wording.

1. What happens next: the small molecule schematic

How targeted therapy works, step by step · animated schematic, not to scale; chosen from the modality "Small-molecule inhibitor"

Targeted Therapy →

2. Step by step

auto-advancing · hover to pause

1.IPG1094 slips into a pocket on its target.

Modality

Small-molecule inhibitor

Mechanism

Described in the registry record as a an inhibitor; the trial entries below carry the sponsor's wording.

Brand / code

IPG1094

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

IPG1094

intervention: IPG1094

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.